Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
RESEARCH TOOLSreports
Holding VTYX?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.53Last Year’s EPS
-0.79Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 23, 2022
|% Change Since: -9.82%
|Next Earnings Date:Nov 17, 2021
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials for multiple drug candidates, particularly VTX3232 and VTX2735. Financial stability was emphasized, despite a consistent net loss and high cash usage. The company appears to be on a promising path with advancements in its pipeline and preparations for future trials.Company Guidance
During the Ventyx Biosciences Q1 2024 earnings call, several key metrics and strategic updates were highlighted. R&D expenses for the quarter were reported at $33.7 million, a slight decrease from $35.4 million in Q1 2023, while G&A expenses rose to $8 million from $7.1 million in the previous year. The company disclosed a net loss of $38.6 million, nearly consistent with the $38.9 million loss in Q1 2023. Cash, cash equivalents, and marketable securities amounted to $302.6 million as of March 31, 2024. Ventyx anticipates a decrease in operating expenses and cash flows in subsequent quarters as it winds down certain Phase II trial programs. With the ongoing development of its NLRP3 inhibitor portfolio, the company aims to advance VTX3232 into Phase II trials for Parkinson's disease and obesity later in 2024, following positive Phase I data. Additionally, VTX2735 showed promising Phase II results in CAPS patients, demonstrating efficacy and safety, which supports its further evaluation for cardiovascular indications. The company is engaged in discussions for potential partnerships to support its Phase III trial for VTX002, following a productive End of Phase 2 meeting with the FDA.Positive Phase I Results for VTX3232
Announced positive top line results from a Phase I trial of VTX3232, showing excellent tolerability and potential best-in-class profile for neuroinflammatory diseases.
VTX2735 Phase II Success
VTX2735 demonstrated efficacy comparable to IL-1 biologics in a Phase II trial for cryoprin-associated periodic syndromes (CAPS), along with robust reductions in inflammatory biomarkers.
VTX002 Phase II Data and Progress
Positive Phase II data for VTX002 in ulcerative colitis, showing potential best-in-disease profile and ongoing preparations for a pivotal Phase III trial.
Financial Stability
Cash, cash equivalents, and marketable securities balance of $302.6 million as of March 31, 2024, sufficient to support planned operations into at least the second half of 2026.
---
VTYX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VTYX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.24 | $2.20 | -1.79% |
| Aug 08, 2024 | $1.98 | $2.07 | +4.55% |
| May 09, 2024 | $4.48 | $4.09 | -8.71% |
| Feb 27, 2024 | $6.05 | $7.77 | +28.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ventyx Biosciences (VTYX) report earnings?
Ventyx Biosciences (VTYX) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Ventyx Biosciences (VTYX) earnings time?
Ventyx Biosciences (VTYX) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTYX EPS forecast?
VTYX EPS forecast for the fiscal quarter 2024 (Q4) is -0.53.
---